Literature DB >> 8637249

Quantification of X-chromosome inactivation patterns in haematological samples using the DNA PCR-based HUMARA assay.

R E Gale1, C A Mein, D C Linch.   

Abstract

Quantification of X-chromosome inactivation patterns (XCIPs) using PCR amplification of the human androgen receptor (HUMARA) locus is potentially valuable in a range of haematological disorders. Of 236 females screened, 203 (86%) were heterozygous. For quantitative XCIPs it was necessary to limit the number of PCR cycles to 20 to reduce preferential amplification of shorter alleles. The optimized PCR method was compared with Southern blotting results using either PGK, HPRT or M27beta in 51 haematologically normal females and blast cells from 27 patients with acute myeloid leukaemia (AML). Reproducible XCIP results were obtained in all 78 samples using digestion with Hpa II prior to amplification (median difference in duplicate values 3%, range 0-17%) and they correlated well with Southern blotting results, r=0.966. Greater variability was observed in the results using Hha I digestion (median difference 4%, range 0-48%). There were marked inconsistencies in repeated analyses of three AML samples and although the HUMARA-Hha I results correlated well overall with Southern blotting in the remaining 75 samples (r=0.922), in nine samples there were still discrepancies with > or = 20% difference between the two values. These results suggest that PCR analysis of the HUMARA locus in Hpa II-digested DNA is suitable for the quantification of XCIPs in haematological samples but results with Hha I should be treated with caution.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8637249

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  A longitudinal study of X-inactivation ratio in human females.

Authors:  Ionel Sandovici; Anna K Naumova; Mark Leppert; Yendi Linares; Carmen Sapienza
Journal:  Hum Genet       Date:  2004-08-28       Impact factor: 4.132

2.  X chromosome-inactivation patterns of 1,005 phenotypically unaffected females.

Authors:  James M Amos-Landgraf; Amy Cottle; Robert M Plenge; Mike Friez; Charles E Schwartz; John Longshore; Huntington F Willard
Journal:  Am J Hum Genet       Date:  2006-07-27       Impact factor: 11.025

3.  Analysis of the distribution of CAG repeats and X-chromosome inactivation status of HUMARA gene in healthy female subjects using improved fluorescence-based assay.

Authors:  M Karasawa; N Tsukamoto; A Yamane; K Okamoto; T Maehara; A Yokohama; Y Nojima; M Omine
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

4.  The human androgen receptor X-chromosome inactivation assay for clonality diagnostics of natural killer cell proliferations.

Authors:  Michaël Boudewijns; Jacques J M van Dongen; Anton W Langerak
Journal:  J Mol Diagn       Date:  2007-07       Impact factor: 5.568

5.  Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).

Authors:  Marilyn L Slovak; Victoria Bedell; Danika Lew; Kathy S Albain; Georgiana K Ellis; Robert B Livingston; Silvana Martino; Edith A Perez; Gabriel N Hortobagyi; Dorie Sher; Wendy Stock
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

6.  A novel, essential control for clonality analysis with human androgen receptor gene polymerase chain reaction.

Authors:  Jeroen P van Dijk; Leonie H Heuver; Bert A van der Reijden; Reinier A Raymakers; Theo de Witte; Joop H Jansen
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

7.  Clonality assay of hematopoietic disorders: significance of the buccal epithelium as non-hematopoietic control and of 95% rejection limit as a novel criterion for monoclonality.

Authors:  H Inagaki; A Wakita; H Komatsu; M Kikuchi; A Inagaki; T Eimoto; R Ueda
Journal:  Jpn J Cancer Res       Date:  2001-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.